Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) EBT Margin (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBT Margin readings, the most recent being 70.37% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 40170.0% to 70.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.07%, a 8801.0% increase, with the full-year FY2025 number at 47.98%, up 3743.0% from a year prior.
  • EBT Margin hit 70.37% in Q4 2025 for Arcadia Biosciences, up from 88.48% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 243.33% in Q2 2023 to a low of 644.32% in Q1 2021.
  • Median EBT Margin over the past 5 years was 67.09% (2024), compared with a mean of 79.05%.
  • The widest YoY moves for EBT Margin: up 244846bps in 2021, down -143300bps in 2021.
  • Arcadia Biosciences' EBT Margin stood at 130.07% in 2021, then tumbled by -58bps to 54.49% in 2022, then crashed by -205bps to 57.27% in 2023, then crashed by -479bps to 331.33% in 2024, then skyrocketed by 121bps to 70.37% in 2025.
  • The last three reported values for EBT Margin were 70.37% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025) per Business Quant data.